Literature DB >> 8772588

Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes.

Q Dong1, F Brucker-Davis, B D Weintraub, R C Smallridge, F E Carr, J Battey, A M Spiegel, A Shenker.   

Abstract

Activating mutations encoding substitutions at positions Arg201 and Gln227 of the alpha-subunit of the stimulatory G protein. G10 have been found in about 40% of pituitary somatotroph tumors. Although the etiology of thyrotroph adenomas is unknown, their autonomous behavior and blunted response to stimulatory hypothalamic hormone superficially resemble those of somatotroph tumors. We hypothesized that a subset of thyrotroph tumors might be caused by dominant somatic mutations that lead to inappropriate activation of the Gq/phospholipase C beta/Ca2+/protein kinase C. pathway normally triggered by occupancy of the TRH receptor (TRHR). We, therefore, screened samples from nine thyrotroph tumors for the presence of activating mutations of the alpha q, alpha 11, and TRHR genes. Fragments of alpha q and alpha 11 complementary DNA encompassing residues (Arg183 and Gln209) that correspond to Arg201 and Gln227 of alpha q were amplified and sequenced. Temperature gradient gel electrophoresis was used to screen for heterozygous mutations in the TRHR coding sequence as well as for known alpha s mutations. No mutations were detected. We conclude that mutations in these regions of the alpha q, alpha 11, alpha s, and TRHR genes occur infrequently, if at all, in human thyrotroph tumors. Alternative mechanisms underlying thyrotroph tumorigenesis, including changes in the expression levels of G protein alpha-subunits or TRHR, dysregulation of downstream components, inappropriate activation of other stimulatory pathways, or loss of inhibitory inputs, remain to be explored.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772588     DOI: 10.1210/jcem.81.3.8772588

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Clinical and molecular features of a TSH-secreting pituitary microadenoma.

Authors:  Takeshi Usui; Shoichiro Izawa; Toshiaki Sano; Tetsuya Tagami; Daisuke Nagata; Akira Shimatsu; Jun A Takahashi; Mitsuhide Naruse
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.

Authors:  P Beck-Peccoz; A Lania; A Beckers; K Chatterjee; J-L Wemeau
Journal:  Eur Thyroid J       Date:  2013-05-07

Review 4.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.

Authors:  C Asteria; M Anagni; L Persani; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

6.  Effects of G-protein mutations on skin color.

Authors:  Catherine D Van Raamsdonk; Karen R Fitch; Helmut Fuchs; Martin Hrabé de Angelis; Gregory S Barsh
Journal:  Nat Genet       Date:  2004-08-22       Impact factor: 38.330

Review 7.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

Review 8.  Biochemical and physiological insights into TRH receptor-mediated signaling.

Authors:  Radka Trubacova; Zdenka Drastichova; Jiri Novotny
Journal:  Front Cell Dev Biol       Date:  2022-09-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.